The contrasting landscape of drug discovery in neuropsychopharmacology. A conversation with Adrian Newman-Tancredi

Adrian Newman-Tancredi; Luc Zimmer

doi:10.1016/j.therap.2020.12.004

The contrasting landscape of drug discovery in neuropsychopharmacology. A conversation with Adrian Newman-Tancredi

Therapie. 2021 Mar-Apr;76(2):71-74. doi: 10.1016/j.therap.2020.12.004. Epub 2020 Dec 5.

Authors

Adrian Newman-Tancredi¹, Luc Zimmer²

Affiliations

¹ Neurolixis, 81100 Castres, France.
² Lyon Neuroscience Research Centre, INSERM, CNRS, Université Claude Bernard Lyon 1, 69675 Bron, France; CERMEP, Hospices Civils de Lyon, 69500 Bron, France; National Institute for Nuclear Science and Technology, INSTN, CEA, 91400 Saclay, France. Electronic address: luc.zimmer@univ-lyon1.fr.

PMID: 33436275
DOI: 10.1016/j.therap.2020.12.004

Abstract

For this issue, Luc Zimmer, professor of pharmacology and chair of the Neuropsychopharmacology Committee of the French Society of Pharmacology and Therapeutics (SFPT), talked with Adrian Newman-Tancredi, neuropharmacologist, co-founder and CEO of a biopharmaceutical company developing clinical-stage central nervous system drugs. They address through experiences the particularities of research in neuropsychopharmacology in the pharmaceutical industry. The evolution of drug discovery strategy is also discussed, as well as the reasons for the contrasting landscape of research for new molecules for psychiatry.

Keywords: Pharmaceutical industry; Preclinical research; Psychiatry; Research & development.

MeSH terms

Drug Discovery*
Drug Industry*
Humans